Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06907953 · ClinicalTrials.gov registry record
CZI Rare As One: Co-designing an App and Wearable Based Compass for Rare Diseases
A clinical trial of Long COVID and Sarcoidosis, sponsored by 4YouandMe.
- Completed
- Registry status
- 239
- Enrollment target
- 1
- Study location
NCT06907953: Completed study of Long COVID and Sarcoidosis, sponsored by 4YouandMe.
NCT06907953 is a study of Long COVID and Sarcoidosis that has completed, run by 4YouandMe. The registered enrollment target is 239 participants, below the 2,183-participant average among 50 other Long COVID trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06907953, a study of Long COVID and Sarcoidosis, has completed, sponsored by 4YouandMe.
- COMPLETED
- Registry status
- 239 participants
- Enrollment target
- 1
- Study location
Study Summary
The CZI Rare As One study is a Chan Zuckerberg Initiative funded study that aims to co-design and pilot test unique symptom tracking and transmitting apps across 5 different sub-arms that includes individuals with Long COVID, Pancreatitis, Sarcoidosis, Vasolin-Containing Protein (VCP) disease and Primary Ciliary disease (PCD). This study aims to use multimodal digital health tools to enable patients to self-monitor their symptoms in passive and active ways.
Primary Outcome
Proportion of participants retained for the full study
Conditions Studied
Interventions
- OTHER Observational - no intervention
Study Locations (1)
New York
- 4YouandMe - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 239 participants |
| Start Date | 2025-02-06 |
| Est. Completion | 2025-07-01 |
What the finished NCT06907953 record still lists
NCT06907953 is an observational study that tracks outcomes without assigning an intervention. The registered 239 participants enrollment target is mid-sized for trials with a published cap, below the 2,183-participant average among 50 other Long COVID trials with a reported enrollment target (89% lower).
The record links to 7 conditions, with Long COVID appearing as the primary indexed condition, and to 1 intervention - of which Observational - no intervention is the first listed.
NCT06907953 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06907953 about?
NCT06907953 is a clinical study titled "CZI Rare As One: Co-designing an App and Wearable Based Compass for Rare Diseases". The CZI Rare As One study is a Chan Zuckerberg Initiative funded study that aims to co-design and pilot test unique symptom tracking and transmitting apps across 5 different sub-arms that includes individuals with Long COVID, Pancreatitis, Sarcoidosis, Vasolin-Containing Protein (VCP) disease and Pr...
What is the current status of trial NCT06907953?
This trial is currently completed. The enrollment target is 239 participants. The study started on 2025-02-06. Estimated completion is 2025-07-01.
What conditions does trial NCT06907953 study?
This clinical trial studies the following conditions: Long COVID, Sarcoidosis, Symptoms and Signs, Pancreatitis, Chronic, Wearables.
What interventions are being tested in trial NCT06907953?
The interventions under investigation include: Observational - no intervention (OTHER).
Who is sponsoring clinical trial NCT06907953?
This trial is sponsored by 4YouandMe, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06907953 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Long COVID
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06907953's enrollment target sits among peer trials
239 13th of 50 higher than 38 of 50 other Long COVID trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Long COVID trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Water-based Activity to Enhance Recovery in Long COVID-19
RECRUITING · NA
-
Non-invasive Treatment for Long COVID (Post COVID-19 Condition) Brain Fog
RECRUITING · NA
-
Long-Covid-19 Alleviation Through Learning Mindfulness Study
RECRUITING · NA
-
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
RECRUITING · Phase 3
-
Sauna for Long Covid
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI